CSPC Pharmaceutical Group Limited (HKG:1093) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year’s forecasts. Consensus estimates suggest investors could expect greatly increased statutory revenues and earnings per share, with analysts modelling a real improvement in business performance.
Following the upgrade, the latest consensus from CSPC Pharmaceutical Group’s 20 analysts is for revenues of CN¥34b in 2026, which would reflect a substantial 31% improvement in sales compared to the last 12 months. Per-share earnings are expected to shoot up 125% to CN¥0.76. Before this latest update, the analysts had been forecasting revenues of CN¥30b and earnings per share (EPS) of CN¥0.58 in 2026. There has definitely been an improvement in perception recently, with the analysts substantially increasing both their earnings and revenue estimates.
See our latest analysis for CSPC Pharmaceutical Group
Although the analysts have upgraded their earnings estimates, there was no change to the consensus price target of HK$11.55, suggesting that the forecast performance does not have a long term impact on the company’s valuation.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the CSPC Pharmaceutical Group’s past performance and to peers in the same industry. The analysts are definitely expecting CSPC Pharmaceutical Group’s growth to accelerate, with the forecast 43% annualised growth to the end of 2026 ranking favourably alongside historical growth of 0.9% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 10% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect CSPC Pharmaceutical Group to grow faster than the wider industry.
The Bottom Line
The most important thing to take away from this upgrade is that analysts upgraded their earnings per share estimates for this year, expecting improving business conditions. Fortunately, analysts also upgraded their revenue estimates, and our data indicates sales are expected to perform better than the wider market. The lack of change in the price target is puzzling, but with a serious upgrade to this year’s earnings expectations, it might be time to take another look at CSPC Pharmaceutical Group.
Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. We have estimates – from multiple CSPC Pharmaceutical Group analysts – going out to 2028, and you can see them free on our platform here.
Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.